Drug Profile
Research programme: cancer therapeutic nanoparticles - Quiet Therapeutics
Alternative Names: GAG-pDNA; GAG-RNA; GAG-SM; GAGomers - Quiet Therapeutics; Hyaluronic acid coated nanoclusters - Quiet Therapeutics; Lipidated glycosaminoglycan nanoparticles - Quiet Therapeutics; Nanovectors - Quiet TherapeuticsLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Quiet Therapeutics
- Developer Tel Aviv University
- Class Nucleic acids; Peptides; Small molecules
- Mechanism of Action DNA intercalators; DNA synthesis inhibitors; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ovarian-cancer in Israel (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Israel (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for research development in Head-and-neck-cancer in Israel